Mid‐term outcome of permanent prostate iodine‐125 brachytherapy in Japanese patients

To analyze mid‐term oncological outcomes of low‐dose rate brachytherapy in Japanese patients.

[1]  N. Keating,et al.  Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? , 2013, European urology.

[2]  W. J. Morris,et al.  Outcomes following iodine-125 brachytherapy in patients with Gleason 7, intermediate risk prostate cancer: a population-based cohort study. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  J. Ciezki,et al.  Long-Term (10-Year) Gastrointestinal and Genitourinary Toxicity after Treatment with External Beam Radiotherapy, Radical Prostatectomy, or Brachytherapy for Prostate Cancer , 2012, Prostate Cancer.

[4]  N. Katayama,et al.  Primary Gleason grade 4 impact on biochemical recurrence after permanent interstitial brachytherapy in Japanese patients with low- or intermediate-risk prostate cancer. , 2012, International journal of radiation oncology, biology, physics.

[5]  J. Blasko,et al.  Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience. , 2011, International journal of radiation oncology, biology, physics.

[6]  P. Unger,et al.  Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. , 2011, The Journal of urology.

[7]  Hiroyuki Takahashi,et al.  Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial , 2010, BMC Cancer.

[8]  R. Stock.  Counterpoint: there is a dose-response relationship in the low-dose rate brachytherapy management of prostate cancer. , 2010, Brachytherapy.

[9]  K. Wallner,et al.  Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. , 2010, International journal of radiation oncology, biology, physics.

[10]  H. Narita.  [Radiation safety control of an implant source and the issue]. , 2009, Nihon Hoshasen Gijutsu Gakkai zasshi.

[11]  Michael W Kattan,et al.  Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. , 2007, International journal of radiation oncology, biology, physics.

[12]  R. Stock,et al.  Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. , 2007, Urology.

[13]  Louis Potters,et al.  Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. , 2007, International journal of radiation oncology, biology, physics.

[14]  Barry S Rosenstein,et al.  Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. , 2005, International journal of radiation oncology, biology, physics.

[15]  M. Kattan,et al.  The prognostic significance of Gleason Grade in patients treated with permanent prostate brachytherapy. , 2003, International journal of radiation oncology, biology, physics.

[16]  Seifter.  Management of prostate cancer , 2000, Journal of the National Cancer Institute.

[17]  T. Matsuda,et al.  Radical retropubic prostatectomy: time trends, morbidity and mortality in Japan , 1999, Prostate Cancer and Prostatic Diseases.

[18]  A. Renshaw,et al.  Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy , 1998, Cancer.

[19]  D. Ash,et al.  Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience. , 2010, International journal of radiation oncology, biology, physics.

[20]  Marco Zaider,et al.  Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. , 2007, International journal of radiation oncology, biology, physics.

[21]  K. Wallner,et al.  Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. , 2005, International journal of radiation oncology, biology, physics.

[22]  L. Potters,et al.  12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. , 2005, The Journal of urology.